# OnCo record paper-a071401-brastianos-jco-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-a071401-brastianos-jco-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-a071401-brastianos-jco-2023" ;
  schema:name "Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations"@en ;
  schema:description "In the first trial to match meningioma patients to a drug by their tumour's mutation, a FAK-blocking tablet kept 83 percent of low-grade and 33 percent of higher-grade NF2-mutant tumours from progressing for six months, clearing the bar the trial had set."@en ;
  schema:url <https://onco.cc/key-papers/paper-a071401-brastianos-jco-2023/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.21.02371>, <https://pubmed.ncbi.nlm.nih.gov/36288512/>, <https://clinicaltrials.gov/study/NCT02523014> ;
  schema:sameAs <https://doi.org/10.1200/JCO.21.02371> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Brastianos PK, Twohy EL, Gerstner ER, et al." ;
  onco:cancers <https://onco.cc/cancers/meningioma/> ;
  onco:targets <https://onco.cc/targets/fak/> ;
  onco:drugs <https://onco.cc/drugs/gsk2256098/> ;
  onco:institutions <https://onco.cc/institutions/alliance-oncology/> ;
  onco:trials <https://onco.cc/trials/a071401/> ;
  onco:journals <https://onco.cc/journals/jco/> .